The independent platform for news, articles and advice for professionals in laboratory medicine

Proclarix introduced into Italian laboratory to assess prostate cancer

Diagnostica Medica and Proteomedix, the Swiss cancer diagnostics company, have announced that Proclarix , a new blood test for the management of prostate cancer patients, has been introduced in the routine of the laboratory.

Proclarix is an innovative decision support tool to improve the diagnostic management of individuals with suspect for prostate cancer. "We are pleased to be the first commercial laboratory in Italy to have included Proclarix in our routine," said Dr Paola Bruni, Head of the Diagnostica Medica laboratory, part of the Neuromed Group. "The test, consisting of an algorithm that brings together prostate cancer-specific biomarkers along with other clinical parameters, will be of great help in the management of patients with suspected prostate cancer," she also added.

"The diagnostic path of prostate cancer has now totally changed. It is necessary to be able to distinguish tumours with low aggressiveness from those with high, the latter deserving in-depth analysis such as a biopsy. Proclarix is a great help in this regard," Dr Stefano Pecoraro, Director of the Functional Urology Area of the Neuromed Group, commented.

Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. In Italy, more than 40,000 new cases of prostate cancer are diagnosed every year and there are about 7000 deaths related to prostate cancer.

"We are pleased with the commercial partnership with Diagnostica Medica that will allow an increasing number of patients to have access to an examination that can reduce invasive procedures and possible complications related to these," said Dr Maurizio Ballerini, Vice President Market Development EMEA at Proteomedix.

Upcoming Events

Transfusing Wisely: a free-to-access SHOT webinar

Online
6 December 2022

Microbiology Society Annual Conference 2023

Birmingham International Convention Centre.
17-20 April 2023

British Society for Microbial Technology Annual Microbiology Conference

Royal Air Force Museum, Hendon, London
10 May 2023

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

IBMS Congress 2023

ICC Birmingham
25-28 September 2023

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Transfusing Wisely: a free-to-access SHOT webinar

Online
6 December 2022

Microbiology Society Annual Conference 2023

Birmingham International Convention Centre.
17-20 April 2023

British Society for Microbial Technology Annual Microbiology Conference

Royal Air Force Museum, Hendon, London
10 May 2023

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

IBMS Congress 2023

ICC Birmingham
25-28 September 2023

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2022 Step Communications Ltd. Registered in England. Registration Number 3893025